231278-08-3

Basic information

• Product Name: 2-AMino-4-fluoro-5-iodo-benzoic acid
• Synonyms: 2-AMino-4-fluoro-5-iodo-benzoic acid
• CAS NO: 231278-08-3
• Molecular Formula: C₇H₅FINO₂
• Molecular Weight: 281.0229732
• EINECS: -0
• Mol File: 231278-08-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-AMino-4-fluoro-5-iodo-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMino-4-fluoro-5-iodo-benzoic acid(231278-08-3)
• EPA Substance Registry System: 2-AMino-4-fluoro-5-iodo-benzoic acid(231278-08-3)

Safety Data

• Hazardous Substances Data: 231278-08-3(Hazardous Substances Data)

Usage

Chemical Structure

Consists of a benzene ring substituted with:
Amino group ( \textNH2 )
Fluoro group ( \textF )
Iodo group ( \textI )

Potential Applications

Pharmaceutical Industry:
May exhibit biological activity
Used in the synthesis of various pharmaceuticals
Chemical Synthesis:
Valuable building block due to fluoro and iodo groups
Enables construction of more complex organic molecules

Intermediate in Organic Synthesis

Importance:
Facilitates the synthesis of other organic compounds
Utility:
Key role in the development of new drugs and materials

Upstream product

• 446-32-2 4-fluoroanthranilic acid 

Relevant articles and documents

QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS

Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compo

An alternative synthesis of the non-small cell lung carcinoma drug afatinib

Afatinib (BIBW2992) is the anticancer drug developed by Boehringer Ingelheim. This work is reporting the synthesis of the afatinib using a new route by Ullmann-Goldberg reaction from corresponding 4-anilinoquinazoline iodide as the last step in the synthesis. This route was not described previously and it could be used for synthesis of afatinib analogues.

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

A pharmaceutical formulation comprising the compound of formula